Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Practice environmental safety in Style: Divulging Famous Electric Vehicle Brands06.06.2024 - 2Dominating the Remote Work Way of life: Individual Systems22.09.2023
- 3It's been 20 years since MTV's golden couple split. These producers saw it all unravel.16.12.2025
- 4Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined05.06.2024
- 5Dramatic Dominance d: A Survey of \Feelings in front of an audience\ Theater Play10.08.2023
- 6 Objections for an Ocean side Wedding
- Why ordering takeout or calling the dog walker might lead to a happier relationship
- The Fate of Rest: Patterns in Shrewd Beds
- Find the Captivating Professional flowerbeds of the US
- The risk of falling space junk hitting airplanes is on the rise, experts warn
- Step by step instructions to Guarantee Your Fender bender Legal counselor has Areas of strength for a Record
- Find the Native Culinary Customs: Local Flavors
- Figure out How to Involve a Brain science Certification in Showcasing
- Manual for Tracking down the Immaculate Magnificence of Focal Asia
